GlassScriptPhysician profile
Lori Darrah
NPI 1699922914
$5,651.47
in general payments reported to CMS, 2019-2025
22 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $243 · 2023: $1,914 · 2024: $1,891 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,939 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,938.75 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $721.19 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $698.53 | 2023-2025 | Zoryve |
| Abbvie INC. | $651.43 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $597.51 | 2021-2024 | Jublia, Targretin, Siliq |
| Genzyme Corporation | $412.26 | 2023-2025 | |
| Leo Pharma INC. | $378.31 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $322.45 | 2022-2025 | Tremfya, Stelara, Remicade |
| Galderma Laboratories, L.P. | $312.79 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $260.46 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $239.10 | 2024-2025 | Tremfya |
| Amgen INC. | $218.94 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $187.77 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $187.19 | 2023-2025 | Ilumya |
| Ucb, INC. | $114.86 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $106.07 | 2023-2024 | Sotyktu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54.43 | 2022-2025 | |
| Almirall LLC | $47.23 | 2023-2024 | Seysara, Klisyri |
| Journey Medical Corporation | $39.78 | 2024 | |
| Organon LLC | $33.90 | 2025 | Vtama |
| Biofrontera INC. | $29.28 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $19.92 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $18.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Darrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.